HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Lowers Price Target to $61
HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $69 to $61.
Barrington Research Reiterates Outperform on Alithya Group, Maintains C$3.5 Price Target
Barrington Research analyst Vincent Colicchio reiterates Alithya Group (TSX:ALYA) with a Outperform and maintains C$3.5 price target.
Credit Suisse Reiterates Outperform on MasTec, Maintains $122 Price Target
Credit Suisse analyst Jamie Cook reiterates MasTec (NYSE:MTZ) with a Outperform and maintains $122 price target.
Benchmark Reiterates Buy on Quipt Home Medical, Maintains $10 Price Target
Benchmark analyst Bill Sutherland reiterates Quipt Home Medical (NASDAQ:QIPT) with a Buy and maintains $10 price target.
EF Hutton Reiterates Buy on Upexi, Maintains $7 Price Target
EF Hutton analyst Michael Albanese reiterates Upexi (NASDAQ:UPXI) with a Buy and maintains $7 price target.
Jefferies Reiterates Buy on Danaos, Maintains $80 Price Target
Jefferies analyst Omar Nokta reiterates Danaos (NYSE:DAC) with a Buy and maintains $80 price target.
EF Hutton Reiterates Buy on Bicycle Therapeutics, Maintains $55 Price Target
EF Hutton analyst Tony Butler reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $55 price target.
HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $50 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $50 price target.
HC Wainwright & Co. Reiterates Buy on Biotricity, Maintains $2 Price Target
HC Wainwright & Co. analyst Kevin Dede reiterates Biotricity (NASDAQ:BTCY) with a Buy and maintains $2 price target.
Needham Reiterates Buy on Bicycle Therapeutics, Maintains $72 Price Target
Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $72 price target.